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Abstract
Background: The transmissible spongiform encephalopathies, otherwise known as prion diseases,
occur following the conversion of the cellular prion protein (PrPC) to an alternatively folded,
disease-associated isoform (PrPSc). Recent studies suggest that this conversion occurs via a
cholesterol-sensitive process, as cholesterol synthesis inhibitors reduced the formation of PrPSc
and delayed the clinical phase of scrapie infection. Since polyunsaturated fatty acids also reduced
cellular cholesterol levels we tested their effects on PrPSc formation in three prion-infected
neuronal cell lines (ScGT1, ScN2a and SMB cells).
Results: We report that treatment with docosahexaenoic acid (DHA), eicosapentaenoic acid
(EPA) or the cholesterol synthesis inhibitor simvastatin reduced the amounts of free cholesterol in
membrane extracts from prion-infected neuronal cells. Simvastatin reduced cholesterol production
while DHA and EPA promoted the conversion of free cholesterol to cholesterol esters. Crucially,
while simvastatin reduced PrPSc formation, both DHA and EPA significantly increased the amounts
of PrPSc in these cells. Unlike simvastatin, the effects of DHA and EPA on PrPSc content were not
reversed by stimulation of cholesterol synthesis with mevalonate. Treatment of ScGT1 cells with
DHA and EPA also increased activation of cytoplasmic phospholipase A2 and prostaglandin E2
production. Finally, treatment of neuronal cells with DHA and EPA increased the amounts of PrPC
expressed at the cell surface and significantly increased the half-life of biotinylated PrPC.
Conclusion: We report that although treatment with DHA or EPA significantly reduced the free
cholesterol content of prion-infected cells they significantly increased PrPSc formation in three
neuronal cell lines. DHA or EPA treatment of infected cells increased activation of phospholipase
A2, a key enzyme in PrPSc formation, and altered the trafficking of PrPC. PrPC expression at the cell
surface, a putative site for the PrPSc formation, was significantly increased, and the rate at which
PrPC was degraded was reduced. Cholesterol depletion is seen as a potential therapeutic strategy
for prion diseases. However, these results indicate that a greater understanding of the precise
relationship between membrane cholesterol distribution, PrPC trafficking, cell activation and PrPSc
formation is required before cholesterol manipulation can be considered as a prion therapeutic.
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Background
Transmissible spongiform encephalopathies (TSEs), also
known as prion diseases, include Creutzfeldt-Jakob dis-
ease and kuru in humans, scrapie in sheep and goats, and
bovine spongiform encephalopathy in cattle. The central
event in these diseases is thought to be the conversion of
a host-encoded cellular prion protein (PrPC) into an
abnormally folded disease-associated isoform, designated
PrPSc [1]. Aggregates of PrPSc accumulate around neurons
in affected brain areas [2], a process which is thought to
lead to neuronal dysfunction and the clinical symptoms
of infection. PrPSc constitutes the major and perhaps the
only component of the infectious particle [3].
The process of prion replication has been studied exten-
sively in prion-infected neuronal cell lines. Treatment
with some cholesterol synthesis inhibitors reduced the
production of PrPSc in scrapie-infected neuronal cells [4-
6]. The anti-prion effect of such drugs is attributed to cho-
lesterol depletion affecting the formation of specialised
membrane micro-domains called lipid rafts [7]. These
lipid rafts are highly enriched in cholesterol, sphingolip-
ids and gangliosides, and contain specific proteins [8].
The presence of a glycosylphosphatidylinositol (GPI)
anchor that mediates the attachment of proteins includ-
ing PrPC and PrPSc to membranes, targets these proteins to
lipid rafts [9].
Since cholesterol levels are a factor determining PrPSc for-
mation [4-6], the effects of compounds reported to affect
cellular cholesterol levels were examined. Polyunsatu-
rated fatty acids (PUFA) are fatty acids which contain two
or more double bonds within their hydrocarbon chain.
They are taken as dietary supplements by large numbers of
people for their perceived health benefits against a variety
of diseases including coronary heart disease, hyperten-
sion, diabetes mellitus and rheumatoid arthritis [10]. The
common PUFA include docosahexaenoic acid (DHA),
eicosapentaenoic acid (EPA), arachidonic acid (AA), lino-
leic acid (LA) and linolenic acid (LNA) and in most cells
PUFA are rapidly incorporated into phospholipids [11].
The incorporation of PUFA into phospholipids alters the
composition and physical properties of cell membranes
[12]. Since dietary PUFA reduce cellular cholesterol levels
[13] the effects of PUFA on the composition of neuronal
cell membranes and on the production of PrPSc were
examined. We report that treatment with DHA or EPA sig-
nificantly reduced the amounts of free cholesterol in
ScGT1, ScN2a and SMB cells. However, in contrast to the
effects of cholesterol synthesis inhibitors, treatment with
DHA or EPA actually increased PrPSc formation. DHA or
EPA treatment also increased the activity of phospholi-
pase A2 (PLA2), an enzyme reported to affect PrPSc forma-
tion [14]. They also increased the amount of PrPC, that is
essential for the development of prion diseases [15,16], at
the cell surface, a putative site for PrPSc formation. In con-
clusion our data indicate that cholesterol depletion per se
does not reduce PrPSc formation.
Results
DHA and EPA increase PrPSc in prion-infected neuronal 
cells
The effect of PUFA on the formation of PrPSc in ScGT1
cells was determined by daily treatment with 1 μM PUFA
for 7 days. Significantly higher amounts of PrPSc were
found in cells treated with DHA (14.2 ng/ml ± 1.7 com-
pared with 8 ± 1, n = 15, P = 0.00000000001) or EPA
(13.8 ng/ml ± 2.4 compared with 8 ± 1, n  = 15, P  =
0.00000002) than in untreated cells, or cells treated with
AA, LA or LNA (Figure 1A). Treatment with DHA or EPA
did not affect the survival of ScGT1 cells (data not shown).
Immunoblots were used to verify the ELISA data; these
showed that there were observable differences in the
amounts of PrPSc between untreated cells and cells treated
with 1 μM DHA or 1 μM EPA (Figure 1B). In contrast, the
amounts of β-actin in untreated cells and cells treated with
DHA or EPA were not significantly different. Determina-
Treatment with DHA or EPA increases the PrPSc content of  ScGT1 cells Figure 1
Treatment with DHA or EPA increases the PrPSc 
content of ScGT1 cells. (A) The amounts of PrPSc in 
ScGT1 cells treated for 7 days with 1 μM PUFA as shown (n) 
or with control medium (h). Values shown are the mean 
average amounts of PrPSc (ng/ml) ± SD, n = 15. # = PrPSc con-
tent significantly higher than that of control cells. (B) Immu-
noblots showing the amounts of β-actin and PrPSc in extracts 
from ScGT1 cells treated with control medium or 1 μM 
DHA or EPA as shown.BMC Biology 2008, 6:39 http://www.biomedcentral.com/1741-7007/6/39
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tion of the effects of different PUFA on PrPSc formation in
ScGT1 cells revealed that whereas treatment with either
DHA or docosapentaenoic (DPA) significantly increased
amounts of PrPSc present, treatment with docosatetrae-
noic acid (DTA) or LA did not. Similarly, while treatment
with EPA increased the amounts of PrPSc in ScGT1 cells,
treatment with eicosatetraenoic acid (ETA) did not. The
effects of DHA, DPA and EPA on the PrPSc content of
ScGT1 cells were dose-dependent (Figure 2).
To confirm that the effects of DHA or EPA were not spe-
cific for ScGT1 cells the amounts of PrPSc in ScN2a and
SMB cells were also examined. The amounts of PrPSc in
ScN2a cells treated for 7 days with 1 μM DHA or 1 μM
EPA, but not in cells treated with LNA, LA or AA, were sig-
nificantly higher than in untreated cells (Table 1). Similar
results were obtained with SMB cells; treatment with DHA
or EPA increased the amounts of cell-associated PrPSc.
Since PrPSc can be released from cells as exosomes or as
result of cell damage [17], the amounts of PrPSc in the
supernatants of treated cells were also measured. The
amounts of PrPSc in the supernatants of ScGT1, ScN2a or
SMB cells treated with 1 μM DHA or 1 μM EPA were sig-
nificantly higher than in supernatants from untreated cells
(Table 1).
DHA and EPA reduced free cholesterol in ScGT1 cells
The effect of 24-hour exposure to PUFA on the cholesterol
content of ScGT1 cell extracts was examined. Exposure to
1 μM DHA or EPA, but not to LNA or LA, significantly
reduced their free cholesterol content (Table 2). None of
the PUFA tested had a significant effect on the amounts of
protein in these extracts (data not shown). The amounts
of free cholesterol in cells treated with DHA or EPA were
similar to those in cells treated with 5 μM simvastatin,
which inhibits 3-hydroxy-3-methylglutaryl-CoA (HMG-
CoA) reductase, the rate-limiting step in cholesterol syn-
thesis [18]. However, total cholesterol is a combination of
free cholesterol found in cell membranes and cholesterol
esters. Simvastatin reduced the amounts of free choles-
terol in cell extracts without affecting the amounts of cho-
lesterol esters, resulting in a reduction in total cellular
cholesterol. In contrast, the total cholesterol content of
ScGT1 cells treated with DHA or EPA was not significantly
altered, as the reduction in free cholesterol was accompa-
nied by significant increases in the amounts of cholesterol
esters. The addition of DHA or EPA to ScN2a or SMB cells
had similar effects; they significantly reduced free choles-
terol levels and increased the cholesterol ester content of
these cells (data not shown).
Such observations raised the possibility that the increased
amounts of cholesterol esters in prion-infected cells facil-
itate PrPSc formation. This possibility was examined by
treating ScGT1 cells with 10 μM cholesterol esters (choles-
terol myristate or cholesterol arachidonate). We report
that although treatment increased the amounts of choles-
terol esters in ScGT1 cells, there were no significant differ-
ences in the amounts of free cholesterol in these cells
(Table 2), indicating that the cholesterol esters were not
hydrolysed. The addition of cholesterol esters did not
affect PrPSc formation; there were no significant differ-
ences between the PrPSc content of vehicle-treated ScGT1
cells and ScGT1 cells treated for 7 days with 10 μM choles-
terol myristate (8.1 ng/ml ± 1.2 compared with 7.9 ± 1.0,
n = 8, P = 0.8) or cholesterol arachidonate (8.1 ng/ml ±
1.2 compared with 8.5 ± 1.7, n = 8, P = 0.6). Similarly, the
addition of cholesterol myristate or cholesterol arachido-
nate did not significantly affect the amounts of PrPSc in
ScN2a cells or in SMB cells (data not shown).
Effects of DHA and EPA are not reversed by mevalonate
The effects of DHA and EPA on cellular cholesterol levels
and PrPSc formation were compared with those of simvas-
tatin. As shown in Figure 3A, the exposure of ScGT1 cells
to 1 μM DHA or EPA for 7 days significantly decreased the
free cholesterol content of cell extracts, as did 5 μM simv-
astatin. However, while the addition of 100 μM meval-
onate significantly increased the amounts of free
cholesterol in simvastatin-treated cells (521 free choles-
terol (ng/ml) ± 45 compared with 356 ng/ml ± 49, n = 9,
Dose-dependent effects of PUFA on PrPSc formation Figure 2
Dose-dependent effects of PUFA on PrPSc formation. 
The amounts of PrPSc in ScGT1 cells treated for 7 days with 
different concentrations of DHA (l), EPA (m), DPA (n), LA 
(n), DTA (h) or ETA (). Values shown are the mean average 
amounts of PrPSc (ng/ml) ± SD, n = 9.BMC Biology 2008, 6:39 http://www.biomedcentral.com/1741-7007/6/39
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P = 0.0002), it did not affect the amounts of free choles-
terol in cells treated with DHA (423 ng/ml ± 40 compared
with 415 ± 43, n = 9, P = 0.4) or EPA (451 ng/ml ± 37 com-
pared with 428 ± 38, n = 9, P = 0.17). Rather, the addition
of mevalonate to DHA-treated cells significantly increased
the amounts of cholesterol esters (225 ng/ml ± 28 com-
pared with 133 ± 31, n = 9, P < 0.01). Next we examined
the effects of mevalonate on PrPSc formation in ScGT1
cells treated with simvastatin, DHA or EPA. The addition
of 100 μM mevalonate significantly increased the
amounts of PrPSc in simvastatin-treated cells (7.4 ng/ml ±
0.5 compared with 1.4 ± 0.9, n = 9, P = 0.00002). In con-
trast, it did not affect the amounts of PrPSc in ScGT1 cells
treated with DHA (13.8 ng/mg ± 1.5 compared with 14.3
± 0.9, n = 9, P = 0.4) or EPA (14.3 ng/mg ± 1.1 compared
with 13.9 ± 1.5, n = 9, P = 0.8), indicating that the effect
of DHA and EPA on PrPSc formation was not due to HMG-
CoA reductase inhibition (Figure 3B).
DHA increases PLA2 activity of prion-infected neuronal 
cells
Since the amounts of activated cytoplasmic PLA2 (cPLA2)
in ScGT1 cells correlates with the amounts of PrPSc [19]
and PLA2  inhibitors reduce PrPSc  formation [14], the
effects of PUFA on the activity of PLA2 in ScGT1 cells was
determined. We report that treatment with 1 μM DHA for
24 hours significantly increased the amounts of phospho-
rylated (activated) cPLA2 in ScGT1 cells (152 units acti-
vated cPLA2 ± 15 compared with 100 ± 9, n  = 9, P  =
0.00001). Treatment with 1 μM EPA for 24 hours also sig-
nificantly increased amounts of activated cPLA2 (142 units
± 13 compared with 100 ± 9, n = 9, P = 0.0001), but treat-
ment with 1 μM AA, LA or LNA had no significant affect
(Figure 4A). The addition of 10 μM cholesterol myristate
did not affect activation of cPLA2 in ScGT1 cells (100 units
± 11 compared with 98 ± 8, n = 9, P = 0.93). This effect of
treatment with 1 μM DHA or EPA was specific for prion-
infected cells and did not affect the amounts of activated
cPLA2 in GT1 cells or primary cortical neurons. To exam-
ine this relationship further we compared the amounts of
PrPSc and activated cPLA2 in ScGT1 cells treated with vary-
ing concentrations of DHA or EPA. There was a positive
correlation between the amounts of activated cPLA2 at 24
hours and the PrPSc content of cells after 7 days (Pearson
coefficient = 0.847, P < 0.001) (Figure 4B).
Table 1: Effects of PUFA on cell-associated and secreted PrPSc
PrPSc (ng/ml)
Treatment ScGT1 cells ScN2A cells SMB cells
Cell extracts Supernatant Cell extracts Supernatant Cell extracts Supernatant
None 8.0 ± 1.0 1.42 ± 0.12 1.38 ± 0.14 0.45 ± 0.09 6.2 ± 1.1 3.1 ± 0.8
1 μM DHA 14.2 ± 1.7 * 4.64 ± 0.73 * 2.91 ± 0.71 * 1.12 ± 0.12 * 16.4 ± 3.7 * 5.7 ± 3.1 *
1 μM EPA 13.8 ± 2.4 * 3.42 ± 0.6 * 3.58 ± 0.52 * 0.96 ± 0.25 * 14.1 ± 2.2 * 4.8 ± 1.2 *
1 μM LA 8.4 ± 1.6 1.38 ± 0.21 1.43 ± 0.2 0.68 ± 0.4 7.7 ± 2.5 2.6 ± 0.75
1 μM LNA 7.8 ± 1.1 1.54 ± 0.46 1.63 ± 0.31 0.51 ± 0.22 7.1 ± 1.8 2.1 ± 1.15
1 μM AA 8.1 ± 1.5 1.56 ± 0.3 1.44 ± 0.3 0.59 ± 0.11 6.4 ± 1.5 2.5 ± 1.26
The amounts of PrPSc in cell extracts (106 cells/ml) and in culture supernatants (equivalent to 106 cells/ml) from prion-infected neuronal cells treated 
for 7 days with 1 μM PUFA as shown. Amounts of PrPSc were measured by PrP-specific ELISA and are expressed as the mean average PrPSc (ng/ml) 
± SD of ScGT1 (n = 15), ScN2a (n = 10) and SMB cells (n = 9). * = amounts of PrPC significantly different from that of untreated cells (P < 0.01).
Table 2: Effects of PUFA on the distribution of cholesterol in ScGT1 cells
Treatment Cholesterol ng/ml
Total Free Esterified
None 590 ± 54 515 ± 29 75 ± 26
DHA (1 μM) 544 ± 39 411 ± 26 # 133 ± 31 @
EPA (1 μM) 553 ± 28 438 ± 25 # 115 ± 20 @
LNA (1 μM) 607 ± 26 548 ± 43 59 ± 18
LA (1 μM) 572 ± 74 495 ± 52 77 ± 28
Simvastatin (5 μM) 438 ± 46 * 354 ± 41 # 84 ± 32
Cholesterol myristate (10 μM) 762 ± 55 * 538 ± 51 224 ± 41 @
Cholesterol arachidonate (10 μM) 734 ± 47 * 545 ± 38 189 ± 32 @
The amounts of total, free and esterified cholesterol in extracts from ScGT1 cells treated for 24 hours with PUFA, simvastatin, or with cholesterol 
esters as shown. Amounts of total, free and esterified cholesterol were expressed as the mean average (ng/ml) ± SD, n = 9. Amounts of total 
cholesterol (*), free cholesterol (#) or esterified cholesterol (@) significantly different from that of untreated cells (P < 0.01).BMC Biology 2008, 6:39 http://www.biomedcentral.com/1741-7007/6/39
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The cPLA2 isoform is largely responsible for the release of
AA and increased production of prostaglandins. Here we
show that the amounts of prostaglandin E2 (PGE2) pro-
duced by ScGT1 cells was significantly increased by 24-
hour treatment with 1 μM DHA (577 ± 89 pg/ml com-
pared with 407 ± 51, n = 9, P = 0.0002) or EPA (568 ± 98
pg/ml compared with 407 ± 51, n = 9, P = 0.001), but not
by LA or LNA (Figure 5A). The addition of 1 μM DHA or
EPA did not affect PGE2 production in GT1 cells. Further-
more, the increased amounts of PrPSc in DHA or EPA-
treated ScGT1 cells showed a positive correlation with the
amounts of PGE2 produced (Pearson's coefficient = 0.749,
P < 0.001; Figure 5B). Treatment with 1 μM DHA also
increased the production of PGE2 in ScN2a cells (319 pg/
ml ± 29 compared with 220 pg/ml ± 24, n = 6, P < 0.01)
and in SMB cells (487 pg/ml ± 89 compared with 355 pg/
ml ± 44, n = 6, P < 0.01).
DHA increases the surface expression of PrPC
Since PrPC is necessary for PrPSc formation [15,16]. the
effects of PUFA treatment on the expression of PrPC were
examined. These studies were initially performed on pri-
mary cortical neurons that do not contain the infectious
PrPSc to avoid any possible confusion between PrPC and
PrPSc. Treatment with 1 μM PUFA for 24 hours did not
affect the total amounts of PrPC in whole cell membrane
extracts. Although PrPC is normally found within lipid raft
The effects of DHA or EPA are not reversed by mevalonate Figure 3
The effects of DHA or EPA are not reversed by 
mevalonate. (A) The amounts of free cholesterol in 
extracts from ScGT1 cells treated for 7 days with control 
medium, 5 μM simvastatin (Sim), 1 μM DHA or 1 μM EPA as 
shown (h), and with the addition of 100 μM mevalonate (n). 
Values shown are the mean average amounts of free choles-
terol (ng/ml) ± SD, n = 9. # = amounts of free cholesterol 
significantly higher following the addition of mevalonate. (B) 
The amounts of PrPSc in ScGT1 cells treated for 7 days with 
control medium, 5 μM simvastatin (Sim), 1 μM DHA, 1 μM 
EPA as shown (h) and with the addition of 100 μM meval-
onate (n). Values shown are the mean average amounts of 
PrPSc (ng/ml) ± SD, n = 9. # = amounts of PrPSc significantly 
higher following the addition of mevalonate.
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DHA and EPA increases the amounts of activated cPLA2 in  ScGT1 cells Figure 4
DHA and EPA increases the amounts of activated 
cPLA2 in ScGT1 cells. (A) The amounts of activated 
(phosphorylated) cPLA2 in untreated ScGT1 cells (h) or 
ScGT1 cells treated with 1 μM PUFA as shown (n). Values 
shown are the mean average amounts of activated cPLA2 
(units) ± SD, n = 12. # = amounts of activated cPLA2 signifi-
cantly higher than that of untreated cells. (B) The amounts of 
activated cPLA2 (units) in ScGT1 cells treated for 24 hours 
with different concentrations of DHA or EPA were plotted 
against the amounts of PrPSc (ng/ml) in ScGT1 cells treated 
for 7 days with the same concentrations of DHA (l) or EPA 
(m).
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micro-domains [9], treatment with 2 μM simvastatin
caused the redistribution of PrPC into the normal bulk
membrane. In contrast, treatment with PUFA did not alter
the distribution of PrPC between lipid rafts and the bulk
membrane (Table 3).
The amounts of PrPC at the cell surface were measured by
digesting neurons with phosphatidylinositol-specific
phospholipase C (PI-PLC). PI-PLC digestion releases GPI-
anchored molecules including PrPC from the cell surface
[20]. The amounts of PrPC released by PI-PLC from 106
cortical neurons treated with 1 μM DHA or 1 μM EPA for
24 hours were significantly higher than the amounts
released from untreated neurons or neurons treated with
10 μM cholesterol esters (Table 4). Treatment with DHA
or EPA for 24 hours also significantly increased the
amounts of surface PrPC in GT1 and ScGT1 cells. It is note-
worthy that the amounts of PrPC released by PI-PLC from
untreated ScGT1 cells were significantly higher than from
untreated GT1 cells (4.1 ng/ml ± 0.8 compared with 1.8 ±
0.6, n = 12, P < 0.01). The effect of DHA or EPA on cell sur-
face PrPC expression contrasted to that of simvastatin,
which reduced surface PrPC expression [21]. When the
amounts of PrPC at the surface of ScGT1 cells treated with
different concentrations of DHA or EPA were plotted
against the amounts of PrPSc in ScGT1 treated for 7 days
with the same concentrations of DHA or EPA, a significant
correlation was observed (Pearson coefficient = 0.832, P <
0.001) (Figure 6).
In a further set of experiments, treated cortical neurons
were pulsed with membrane-impermeable biotin and the
amounts of biotinylated-PrPC in cell membranes were
determined at time points thereafter. The amounts of
biotinylated-PrPC in neuronal extracts were reduced in a
time-dependent manner. Significantly, in neurons treated
with 1 μM DHA or EPA the amounts of biotinylated PrPC
remaining in extracts after 3, 6, 12, 24 or 48 hours were
significantly greater than those in extracts from untreated
cells. While the half-life of biotinylated PrPC in untreated
neurons was approximately 4 hours, in DHA or EPA-
treated neurons the half-life was increased to approxi-
mately 24 hours (Figure 7).
Discussion
The main goal of this study was to investigate the effects
of PUFA on the production of PrPSc, a biochemical marker
for the infectious agent of prion diseases. We report that
treatment with DHA or EPA, but not with AA, LA or LNA,
consistently increased the amounts of PrPSc within three
prion-infected neuronal cell lines (ScGT1, ScN2a and SMB
cells). This effect of PUFA correlated with the number of
unsaturated bonds in the acyl chain; increased PrPSc con-
tent was observed in ScGT1 cells treated with DHA (six
unsaturated bonds) and EPA or DPA (five), while treat-
ment with PUFA containing four or less unsaturated
bonds (AA, DTA, ETA, LNA or LA) did not affect PrPSc for-
mation. The increased PrPSc content of DHA or EPA-
treated cells was accompanied by increased PrPSc content
of culture supernatants, indicating that this treatment did
not prevent the release of PrPSc via exosomes or cell dam-
age.
Cholesterol synthesis inhibitors disrupt lipid rafts and
reduced PrPSc formation [4,5]. More recently, observa-
tions that cholesterol synthesis inhibitors delay experi-
mental scrapie [22,23] increased the interest in the
concept of cholesterol reduction as a means of treating
prion diseases. PUFA are reported to reduce cellular cho-
lesterol and here we show that treatment with DHA and
DHA and EPA increase the amounts of PGE2 in ScGT1 cells Figure 5
DHA and EPA increase the amounts of PGE2 in 
ScGT1 cells. (A) The amounts of PGE2 produced by 
untreated ScGT1 cells (h) or by ScGT1 cells treated for 24 
hours with 1 μM PUFA as shown (n). Values shown are the 
mean average amounts of PGE2 (pg/ml) ± SD, n = 9. # = PGE2 
content significantly higher than that of control cells. (B) The 
amounts PGE2 (pg/ml) in ScGT1 cells treated for 24 hours 
with different concentrations of DHA or EPA were plotted 
against the amounts of PrPSc (ng/ml) in ScGT1 cells treated 
for 7 days with the same concentrations of DHA (l) or EPA 
(m).
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EPA significantly reduced the free cholesterol content of
ScGT1 cells. However, the effects of DHA or EPA on cellu-
lar cholesterol differed from those of the HMG-CoA
inhibitor simvastatin. For example, treatment with simv-
astatin, but not with DHA or EPA, significantly reduced
total cholesterol levels. The reduction in free cholesterol
levels seen in ScGT1 cells treated with DHA and EPA was
accompanied by a significant increase in the amounts of
cholesterol esters, and the total cholesterol content of
DHA and EPA-treated cells was not significantly different
from that of untreated cells. Although the increase in the
PrPSc content of DHA and EPA-treated cells was accompa-
nied by an increase in cholesterol esters, the addition of
cholesterol esters did not increase PrPSc formation, sug-
gesting that the relationship between cholesterol esters
and PrPSc is casual rather than causal. Furthermore, the
effects of DHA and EPA on cholesterol ester formation
were independent of prion-infection; DHA and EPA
increased cholesterol esters in uninfected N2a or GT1 cell
lines and in primary cortical neurons (data not shown).
The amount of free cholesterol in cell membranes is partly
determined by their fatty acid composition; the solubility
of free cholesterol is dependent on the hydrophobic envi-
ronment produced by the tight packing of saturated fatty
acids [24]. The presence of double bonds in unsaturated
fatty acids causes the acyl chain to be kinked; as a result,
phospholipids containing PUFA cannot pack as tightly as
phospholipids containing saturated fatty acids and do not
sequester as much free cholesterol. Thus, the remodelling
of membrane phospholipids to include increased
amounts of DHA or EPA is expected to reduce the capacity
of membranes to solubilise free cholesterol. The amounts
of free cholesterol within cell membranes is tightly con-
trolled [25,26] and excess free cholesterol trafficking into
the endoplasmic reticulum (ER) is esterified by acyl-coen-
zyme A: cholesterol acyltransferase (ACAT) and stored in
cytoplasmic droplets [27]. Our results are consistent with
the hypothesis that treatment with DHA and EPA reduces
the capacity of cell membranes to solubilise free choles-
terol, resulting in increased cholesterol ester formation.
This hypothesis also explains the observation that the
addition of mevalonate did not reverse the effects of DHA
and EPA. While mevalonate increased the amounts of free
cholesterol in simvastatin-treated cells, in DHA or EPA-
treated cells the newly synthesised cholesterol was not
held in the membrane and was rapidly esterified. Simi-
Table 3: Treatment with PUFA does not affect the amounts of PrPC in neuronal membranes
Treatment PrPC (ng/ml)
Whole cell extract Lipid raft fraction Bulk fraction
None 31.6 ± 4.8 25.5 ± 2 2.9 ± 0.9
1 μM AA 30.2 ± 3.1 26.8 ± 2.9 2.8 ± 0.5
1 μM DHA 33.2 ± 4.4 26.6 ± 3.4 3.8 ± 0.8
1 μM EPA 34.5 ± 2.9 27.8 ± 3.1 3.1 ± 0.3
1 μM LA 29.9 ± 4.1 25.9 ± 2.8 3.4 ± 0.8
1 μM LNA 28.8 ± 4.7 24.5 ± 2 3.5 ± 1.2
2 μM Simvastatin 35.6 ± 4.2 7.2 ± 2.2 * 25.9 ± 3.8 *
The amounts of PrPC in whole cell extracts, detergent insoluble membranes (lipid raft fraction) and the detergent soluble membrane (bulk fraction) 
from primary cortical neurons treated with 1 μM PUFA or 2 μM simvastatin for 24 hours. Amounts of PrPC were measured by ELISA and are 
expressed as the mean average PrPC (ng/ml) ± SD, n = 12. * = amounts of PrPC significantly different from that of untreated cells (P < 0.01).
DHA and EPA increase the amounts of PrPC at the surface of  ScGT1 cells Figure 6
DHA and EPA increase the amounts of PrPC at the 
surface of ScGT1 cells. The amounts of PrPC (ng/ml) 
released from the surface of ScGT1 cells treated for 24 
hours with different concentrations of DHA or EPA were 
plotted against the amounts of PrPSc (ng/ml) in ScGT1 cells 
treated for 7 days with the same concentrations of DHA (l) 
or EPA (m).
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larly, while the addition of mevalonate reversed the effects
of simvastatin on PrPSc formation, it did not reverse the
effects of DHA and EPA.
So how could changes in membrane composition affect
PrPSc  formation? The composition of cell membranes
affects the aggregation of PrPSc and fibril formation [28].
Therefore, changes in cell membranes induced by DHA
and EPA may enhance the conversion of small PrPSc oli-
gomers, that are thought to be sensitive to protease diges-
tion (PrPSc-sen) [29], into the larger fibrillar, protease-
resistant deposits of PrPSc. The amount of free cholesterol
in cell membranes is also instrumental in the formation of
lipid rafts [7]. These contain many signalling molecules,
and an emerging paradigm is that of cell activation occur-
ring as a consequence of individual rafts coalescing to
form a platform capable of sustained cell activation.
Therefore, changes in membrane free cholesterol caused
by the incorporation of DHA or EPA into membrane
phospholipids may affect lipid-raft formation and associ-
ated cellular functions [30,31]. In this study we examined
the effects of PUFA treatment on PLA2 activity, as PLA2 has
a critical role in PrPSc formation [14]. As activation of PLA2
in ScGT1 cells is cholesterol-sensitive [5], treatment with
DHA or EPA was expected to reduce PLA2 activity. How-
ever, they significantly increased PLA2 activity and PGE2
production in ScGT1, ScN2a and SMB cells. The mecha-
nisms by which DHA or EPA increased activation of PLA2
are unclear. Since DHA triggers the formation of lipid rafts
[32] it is possible that treatment with DHA or EPA
strengthens the association between PLA2 and PrPSc within
a lipid raft. However, it should be noted that DHA may
have other physical effects on membrane properties that
are independent of cholesterol reduction [33]. For exam-
ple, in some cells DHA released from membrane phos-
pholipids by PLA2 is metabolised into docosanoids [34].
The effects of such DHA metabolites are only just being
elucidated and the possibility that specific docosanoids
affect PrPSc formation cannot be discounted. Similarly,
PUFA have been reported to affect gene regulation [35]
and we do not exclude the possibility that the effects of
DHA or EPA on PrPSc formation result from gene activa-
tion.
We examined the possibility that the increased PrPSc pro-
duction in DHA or EPA-treated cells might be a conse-
quence of their effects on the expression of PrPC.
Table 4: Treatment with DHA or EPA increases the amounts of PrPC at the cell surface
Treatment Cell surface PrPC (ng/106 cells)
Cortical Neurons GT1 cells ScGT1 cells
None 2.9 ± 0.4 1.8 ± 0.6 4.1 ± 0.8
1 μM AA 3.1 ± 0.4 2.1 ± 0.4 3.7 ± 1.1
1 μM DHA 4.8 ± 0.4 # 3.1 ± 0.6 # 8.6 ± 1.6 #
1 μM EPA 4.5 ± 0.5 # 2.8 ± 0.5 # 6.7 ± 1.2 #
1 μM LA 3.4 ± 0.6 2.5 ± 0.6 5 ± 0.7
1 μM LNA 3.2 ± 0.6 2.3 ± 0.5 5.8 ± 0.8 #
2 μM Simvastatin 0.6 ± 0.3 * 0.5 ± 0.2 * 0.7 ± 0.4 *
The amounts of PrPC at the surface of 106 cells treated with 1 μM PUFA or 2 μM simvastatin for 24 hours were measured following digestion with 
PI-PLC (0.2 units/ml). Amounts of PrPC were measured by ELISA and are expressed as the mean average PrPC (ng/106 cells) ± SD, n = 12. # = 
amounts of PrPC significantly higher than that of untreated cells (P < 0.01). * = amounts of PrPC significantly lower than that of untreated cells (P < 
0.01).
DHA and EPA increase the half-life of surface PrPC in neu- rons Figure 7
DHA and EPA increase the half-life of surface PrPC in 
neurons. The amounts of biotinylated-PrPC in untreated 
neurons (l), neurons treated with 1 μM DHA (s) or neurons 
treated with 1 μM EPA (m) measured in cell extracts taken at 
different time points after biotinylation. Values shown are the 
mean average amounts of biotinylated-PrPC (Units) ± SD, n = 
9.
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Treatment of neurons with DHA or EPA did not affect the
total amounts of PrPC in cell extracts, or the distribution
of PrPC between lipid rafts and the bulk membrane. How-
ever, it significantly increased the amounts of PrPC
expressed at the cell surface. This effect of DHA and EPA
contrasted with that of the cholesterol synthesis inhibitors
simvastatin or lovastatin, which reduced surface PrPC
expression [21]. Prior studies indicated that PrPC, but not
PrPSc, is released from cell membranes following PI-PLC
digestion [20], and in the present studies, the PrP released
from ScGT1 cells was protease-sensitive, indicating that
the PrP released was indeed PrPC. These assays were also
performed on non-infected GT1 cells and cortical neurons
with similar results; treatment with either DHA or EPA sig-
nificantly increased the amounts of PrPC at the cell sur-
face, showing that the effects of DHA or EPA on PrPC
expression were not secondary to their effects on PrPSc for-
mation.
These observations are relevant as antibody studies sug-
gest that the conversion of PrPC to PrPSc occurs at the cell
surface or after internalisation from the cell surface [36].
Our hypothesis, that treatment with DHA or EPA
increases the amount of PrPC at the cell surface, a site
where it could be readily converted to PrPSc, is supported
by the positive correlation obtained between the amounts
of PrPC at the cell surface and PrPSc in ScGT1 cells. In addi-
tion, the half-life of surface PrPC was greatly increased in
DHA or EPA-treated cells. Taken together these results
suggest that treatment with DHA or EPA alters endocytosis
and intracellular trafficking of PrPC, consistent with
reports that the intracellular trafficking of PrPC is critical
for PrPSc formation [37,38]. The effect of DHA or EPA on
PrPC is relevant not only for prion diseases but may also
have implications for Alzheimer's disease. The cellular
PrPC present in lipid rafts inhibits beta-secretase activity,
reducing the cleavage of amyloid precursor protein and
amyloid β formation [39]. Thus the regulation of PrPC lev-
els may represent an innovative approach for the modula-
tion of amyloid deposition in the brain of individuals
affected by Alzheimer's disease.
Conclusion
We have shown that treatment of prion-infected cells with
DHA or EPA alters the composition of cell membranes; it
decreased amounts of free cholesterol and increased cho-
lesterol esters. In contrast to the effects of cholesterol syn-
thesis inhibitors, treatment with DHA or EPA increased
PrPSc  formation. Treatment with DHA or EPA greatly
increased the expression of PrPC at the cell surface, a puta-
tive site for PrPSc formation, and altered cell signalling
activity within prion-infected cells, increasing the activa-
tion of PLA2 that is required for PrPSc formation [14]. Cho-
lesterol depletion has been proposed as a therapeutic
strategy for prion diseases, based on reports that choles-
terol synthesis inhibitors reduced PrPSc formation. The
studies reported here demonstrate that cholesterol deple-
tion per se does not reduce PrPSc formation and cautions
against such an approach. While these observations pro-
vide some insight into the composition of lipid rafts and
the activation of signalling pathways that initiate the for-
mation of PrPSc, future studies are needed to examine the
precise relationship between free cholesterol, PrPC expres-
sion and PrPSc formation.
Methods
Cell lines
Prion-infected ScGT1, ScN2a or SMB neuronal cell lines
were grown in Ham's F12 medium supplemented with 2
mM glutamine, 2% foetal calf serum (FCS) and standard
antibiotics (100 U/ml penicillin and 100 μg/ml strepto-
mycin). To measure the effect of PUFA on PrPSc formation,
ScGT1, ScN2a or SMB cells were plated in 6-well plates
(105 cells/well) and cultured in the presence of PUFA,
mevalonate or simvastatin. Cells were grown with daily
changes of media and the amounts of cell-associated PrPSc
were evaluated after 7 days. Cells were washed twice in
phosphate-buffered saline (PBS) before cell extracts were
obtained. Spent medium was collected daily to see if PrPSc
was released into the supernatant. Spent media was
digested with proteinase K (1 μg/ml for 1 hour at 37°C);
digestion was stopped with mixed protease inhibitors.
The digested supernatant was concentrated by centrifuga-
tion with a 30 kDa filter and diluted to an equivalent of
106 cells/ml.
Primary neuronal cultures
Primary cortical neurons were prepared from the brains of
mouse embryos (day 15.5) after mechanical dissociation,
cell sieving and isolation on histopaque (Sigma, Poole,
UK). Neuronal precursors were plated (106 cells/well) in
24-well plates coated with 5 μg/ml poly-L-lysine) in
Ham's F12 containing 5% FCS for 2 hours. Cultures were
shaken (600 rpm for 5 minutes) and non-adherent cells
removed by two washes in PBS. Neurons were grown in
neurobasal medium (NBM) containing B27 components
(Invitrogen, Paisley, UK) for 7 days before they were incu-
bated with test compounds. Immunohistochemistry
showed that less than 3% of cells stained for GFAP (astro-
cytes) or for F4/80 (microglial cells).
Membrane extracts
Cells were homogenised in a buffer containing 10 mM
Tris-HCL, 150 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-
40, 0.5% sodium deoxycholate, 0.2% sodium dodecyl
sulphate (SDS) at 106 cells/ml. Mixed protease inhibitors
(AEBSF, Aprotinin, Leupeptin, Bestain, Pepstatin A and E-
46 (Sigma)) were added to some cell extracts. Membranes
were prepared by repeated passage with a Wheaton
homogeniser; nuclei and large fragments were removedBMC Biology 2008, 6:39 http://www.biomedcentral.com/1741-7007/6/39
Page 10 of 12
(page number not for citation purposes)
by centrifugation (300 × g for 5 minutes). To determine
the amount of PrPSc, whole cell extract was digested with
1 μg/ml proteinase K for 1 hour at 37°C, and digestion
was stopped with mixed protease inhibitors. Digestion of
GT1 cell extracts with 1 μg/ml proteinase K for 1 hour at
37°C completely reduced the PrP signal; that is, complete
digestion of PrPC was achieved. The soluble material was
split into two samples, one of which was heated to 95°C
for 5 minutes and tested in a PrP-specific ELISA (see
below). The other sample was mixed 1:1 with Laemmli
buffer (Bio-Rad) containing β-mercaptoethanol and
boiled for 5 minutes. This fraction was run on a 12% poly-
acrylamide gel (Invitrogen, Paisley, UK). Proteins were
transferred onto a Hybond-ECL nitrocellulose membrane
(Amersham Biosciences, UK) by semi-dry blotting. Mem-
branes were blocked using 10% milk powder, and PrP was
detected by incubation with a mouse monoclonal anti-
body (mAb) ICSM18 (D-Gen, http://www.d-gen.co.uk),
followed by biotinylated rabbit anti-mouse IgG (Dako,
Ely, UK) and ExtrAvidin-peroxidase (Sigma). Detection of
bound antibody was by the enhanced chemiluminescence
kit (Amersham Biosciences). Non-digested samples were
boiled in Laemmli buffer containing β-mercaptoethanol
for 5 minutes and run on a 15% polyacrylamide gel. Pro-
teins were transferred onto a Hybond-P PVDF membrane
(Amersham Biotech, UK) by semi-dry blotting. Mem-
branes were blocked using 10% milk powder and β-actin
was detected by incubation with a mouse mAb (clone AC-
74, Sigma). Detection of bound antibody was by the
enhanced chemiluminescence kit.
Isolation of detergent-resistant membranes (lipid rafts)
To differentiate between the normal bulk membrane and
the lipid raft micro-domains, cells were homogenised in
an ice-cold buffer containing 1% Triton × 100, 10 mM
Tris-HCl, 150 mM NaCl, 10 mM EDTA and mixed pro-
tease inhibitors at 106 cells/ml (as above). Membranes
were prepared by repeated passage with a Wheaton
homogeniser and nuclei and large fragments were
removed by centrifugation (300 × g for 5 minutes at 4°C).
The subsequent post-nuclear supernatant was incubated
on ice (4°C) for 1 hour and centrifuged (16,000 × g for 30
minutes at 4°C). The supernatant was reserved as the nor-
mal bulk membrane while the insoluble pellet was
homogenised in warm extraction buffer containing 10
mM Tris-HCL, 150 mM NaCl, 10 mM EDTA, 0.5% Noni-
det P-40, 0.5% sodium deoxycholate, 0.2% SDS and
mixed protease inhibitors at an equivalent of 106 cells/ml,
and centrifuged (10 minutes at 16,000 × g); the soluble
material was reserved as the lipid raft fraction.
PrP ELISA
The amount of PrP present in cell extracts was determined
in a sandwich ELISA using commercially available,
defined mAbs as previously described [19]. Briefly, Nunc
Maxisorb immunoplates were coated with 0.5 μg/ml mAb
ICSM18 (D-Gen) which recognises amino acids 146 to
159 of murine PrP [40]. Samples were applied and
detected with biotinylated mAb ICSM35 (D-Gen) (which
recognises an epitope between amino acids 91 and 110)
[41]. Biotinylated mAb was detected using extravidin-
alkaline phosphatase and 1 mg/ml 4-nitrophenyl phos-
phate in a diethanolamine buffer (Sigma). Absorbance
was measured on a microplate reader at 450 nm and the
amount of PrP in cell extracts was calculated by reference
to a standard curve of recombinant murine PrP (Prionics,
Zurich, Switzerland); its limit of detection was 50 pg/ml.
Activated cPLA2 ELISA
The activation of cPLA2 is accompanied by phosphoryla-
tion of the 505 serine residue which can be measured by
phospho-specific antibodies. The amounts of activated
cPLA2 in cells were measured by a sandwich ELISA using a
capture antibody (mouse mAb anti-cPLA2, clone CH-7,
Upstate, Milton Keynes, UK) and a rabbit polyclonal anti-
phospho-cPLA2 (Cell Signalling Technology). Bound anti-
bodies were detected with biotinylated anti-rabbit IgG
(Dako), extravidin-alkaline phosphatase and 1 mg/ml 4-
nitrophenyl phosphate in a diethanolamine buffer
(Sigma). Absorbance was measured at 450 nm and the
amounts of activated cPLA2 were calculated from a stand-
ard curve using nonlinear regression. Samples were
expressed as 'units cPLA2' where 100 units was defined as
the amount of activated cPLA2 in 106 untreated cells. A
standard curve was generated from this sample using
sequential log 2 dilutions (range 100 to 1.56 units/well).
PGE2 assay
The amounts of PGE2 produced by cells were determined
by using an enzyme-immunoassay kit (Amersham Bio-
tech, Amersham, UK) according to the manufacturer's
instructions. This assay is based on competition between
unlabelled PGE2 in the sample and a fixed amount of
labelled PGE2 for a PGE2-specific antibody. The detection
limit of this assay is 20 pg/ml.
Quantification of cell surface PrPC
The amounts of PrPC expressed at the cell surface were
determined by treating cells with 0.2 units of PI-PLC for 1
hour at 37°C (106 cells/ml). PI-PLC is cell-impermeable
and acts on the GPI anchors that tether some proteins,
including PrPC, to the cell surface. The amounts of PrPC
released into the culture supernatant following PI-PLC
digestion were measured by PrP ELISA (as above).
Half-life of PrPC
The half-life of surface PrPC in neurons was determined by
incubating 106 cells with PBS containing 10 μg/ml mem-
brane-impermeable sulfo-biotin-X-NHS (Pierce, Cram-
lington, UK) for 10 minutes. Cells were washed four timesBMC Biology 2008, 6:39 http://www.biomedcentral.com/1741-7007/6/39
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with ice-cold PBS containing 10% FCS to remove
unbound biotin and incubated in fresh NBM. Cell extracts
were collected 1, 3, 6, 12, 24 and 48 hours later. The
amounts of biotinylated PrPC in cell extracts were meas-
ured in a modified ELISA. Maxisorb Immunoplates
(Nunc, Rosklide, Denmark) were pre-coated with 10 μg/
ml streptavidin (Sigma) and blocked with 10% milk pow-
der. Samples were added for 1 hour and the amounts of
bound biotinylated PrPC were determined by incubation
with the PrP-specific mouse mAb 4F2, anti-mouse IgG-
alkaline phosphate and 1 mg/ml 4-nitrophenyl phos-
phate in a diethanolamine buffer. Absorbance was meas-
ured at 450 nm. The amounts of biotinylated PrPC were
expressed as units, where 100 units equalled the amount
of biotinylated-PrPC in 106 untreated neurons 1 hour after
biotinylation.
Cholesterol and protein content
Cellular cholesterol and protein content were determined
in cell extracts. Protein concentrations were measured
using a micro-BCA protein assay kit (Pierce, Cramlington,
UK). The amounts of cholesterol were measured using the
fluorometric Amplex Red cholesterol assay kit (Invitro-
gen), according to the manufacturer's instructions. Briefly,
cholesterol is oxidised by cholesterol oxidase to yield
hydrogen peroxide and ketones. The hydrogen peroxide
reacts with 10-acetyl-3, 7-dihydroxyphenoxazine (Amplex
Red reagent) to produce highly fluorescent resorufin,
which is measured by excitation at 550 nm and emission
detection at 590 nm. By performing the assay in the pres-
ence or absence of 50 units/ml cholesterol esterase and 20
μM TMP-15, which inhibits the esterification of free cho-
lesterol, the assay can also determine the amounts of
esterified cholesterol within samples.
Reagents
AA, DHA, DPA, DTA, EPA, ETA, LA, LNA, cholesterol myr-
istate and cholesterol arachidonate were supplied by
Sigma. Stock solutions were made in chloroform/metha-
nol mixtures and frozen at 10 mM; they were thawed and
diluted on the day of use. Mevalonate and simvastatin
were from Calbiochem, Nottingham, UK.
Statistical analysis
Comparison of treatment effects was carried out using one
and two-way analysis of variance techniques as appropri-
ate. Post hoc comparisons of means were performed as
necessary. For all statistical tests significance was set at the
1% level.
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